Find your next paid study

Palette Life Sciences, Inc.NCT07850804

~$10 – $1,050

Actual pay is set by the research site.

Disordered Eating Behaviors

The Balanced and Empowered Eating (BEET) in Diabetes Feasibility Trial

Disordered eating behaviors (DEBs, e.g., binge eating or restrictive eating) can significantly impact type 2 diabetes (T2D) self-management and engagement in t…

University of Colorado, DenverNCT06247514

Actual pay is set by the research site.

Deep Learning-enhanced Personalized Monitoring of Aortic Stenosis - The DETECT-AS Prognostic Study

This study will evaluate the validity of a digital biomarker score for precision risk stratification among older adults with aortic sclerosis or mild aortic st…

Aortic Stenosis

Yale UniversityNCT06749132

Actual pay is set by the research site.

Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer

Phase II Study Evaluating the Effect of IMNN-001 on Second Look Laparoscopy (SLL) in Combination With Bevacizumab (BEV) and Neoadjuvant Chemotherapy (NACT) in Newly Diagnosed With Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer

This is a 1:1 randomized, open label, multi-center phase I/II trial to evaluate the safety, dosing, efficacy, and biological activity of adding IMNN-001 to che…

~$150 – $4,500

Actual pay is set by the research site.

ImunonNCT05739981

Cutaneous T-cell Lymphoma

A Phase Ib Trial Combining Bexarotene With Ultra-Low Dose Total Skin Electron Beam (Tseb) Radiotherapy For The Treatment Of Diffuse Cutaneous T-Cell Lymphomas

The researchers are doing this study to test the safety of combining bexarotene with TSEB radiotherapy in people who have a common form of CTCL called mycosis …

Memorial Sloan Kettering Cancer CenterNCT05296304

~$150 – $3,000

Actual pay is set by the research site.

Head and Neck Squamous Cell Carcinoma (HNSCC)Pancreatic AdenocarcinomaNon-small Cell Lung Cancer (NSCLC)+3 more

A Phase 1/2 Open-label Multicenter Study to Assess the Safety, Pharmacokinetics, and Anti-tumor Activity of GTAEXS617 in Patients With Advanced Solid Tumors

The primary purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of GTAEXS617 (REC-617) in participants w…

Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.

~$150 – $4,200

Actual pay is set by the research site.

Optical Coherence Tomography of RetinaAlzheimer Disease

Comparative Study of High Performance Low-Cost Optical Coherence Tomography

The purpose of this study is to complete performance testing of our custom optical coherence tomography (OCT) device to verify it can deliver retinal images of…

Duke UniversityNCT07425106

Actual pay is set by the research site.

Phase 3

Multinational, Interventional, 52-week, Open-label, Single-arm Study to Evaluate the Treatment Outcomes of Anifrolumab 120 mg Subcutaneous Once Weekly in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus (SUNFLOWER)

The purpose of the SUNFLOWER study is to describe clinical outcomes, including DORIS remission, achieved following the initiation of anifrolumab 120 mg SC once…

Systemic Lupus Erythematosus

~$50 – $2,250

Actual pay is set by the research site.

AstraZenecaNCT07430306

B-cell MalignancyMarginal Zone LymphomaFollicular Lymphoma+7 more

A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies

Study consists of two main parts to explore tacabrutideg recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and mo…

BeOne MedicinesNCT05006716

~$150 – $4,500

Actual pay is set by the research site.

Cardiac Output and Fatigue in Friedreich's Ataxia

This is a clinical trial examining to impact of aerobic training plus omaveloxolone in FRDA. Thirty individuals with FRDA will be recruited; 20 individuals wil…

Friedreich's Ataxia

MASH - Metabolic Dysfunction-Associated Steatohepatitis

~$10 – $1,125

Actual pay is set by the research site.

Scott BarbutoNCT07444333

Phase 2

A Parallel Treatment Group, Phase 2a, Double-blind, 4-arm Trial to Evaluate the Safety, Exposure, and Efficacy of HU6 Compared With Placebo in Male and Female Participants Aged 30 Years or Older With Metabolic Dysfunction-associated Steatohepatitis (MASH)

Rivus Pharmaceuticals. Inc. is sponsoring this research study to assess the safety and tolerability of HU6 as a possible treatment for patients diagnosed with …

Rivus Pharmaceuticals, Inc.NCT07491458

~$75 – $2,800

Actual pay is set by the research site.

Deimplementation of Inappropriate Feeding Practices in Early Care and Education Settings

Arkansas and Louisiana have among the highest rates of adult obesity in the United States at 38.7% and 38.6%, respectively. Prevention and intervention efforts…

Obesity, Childhood